Several authors have highlighted the importance of a good response to chemotherapy in multiple myeloma (MM), especially in first line.
The ongoing introduction of novel therapies for MM provides clinicians and patients various treatment options in numerous lines of treatment.
Real world evidence (RWE) is increasingly important in guiding reimbursement, but also treatment decisions, as HTAs, health insurers and clinicians
Sze Chim (Lewis) obtained a PhD (Dr. rer. nat.) in Biology from Eberhard Karls Universität Tübingen, Germany. His dissertation topic was to